ProMIS Neurosciences Inc
PMN0.760USD
-0.006-0.85%
Market hours （ET）Quotes delayed by 15 min
24.84MMarket Cap
LossP/E TTM
More Details of ProMIS Neurosciences Inc Company
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.
Company Info
Ticker SymbolPMN
Company nameProMIS Neurosciences Inc
IPO dateApr 03, 2017
CEOMr. Neil K. Warma
Number of employees- -
Security typeOrdinary Share
Fiscal year-endApr 03
AddressSuite 200, 1920 Yonge Street
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM4S 3E2
Phone14168476898
Websitehttps://www.promisneurosciences.com/
Ticker SymbolPMN
IPO dateApr 03, 2017
CEOMr. Neil K. Warma
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
129.92K
+13.05%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
101.12K
+2.05%
Mr. Eugene W. Williams
Mr. Eugene W. Williams
Chairman of the Board
Chairman of the Board
--
--
Ms. Anne Marie Fields
Ms. Anne Marie Fields
Managing Director
Managing Director
--
--
Ms. Maggie Shafmaster, Ph.D.
Ms. Maggie Shafmaster, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Josh Mandel-Brehm
Mr. Josh Mandel-Brehm
Independent Director
Independent Director
--
--
Mr. Neil K. Warma
Mr. Neil K. Warma
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Johanne Kaplan, Ph.D.
Dr. Johanne Kaplan, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Larry Altstiel, M.D., Ph.D.
Mr. Larry Altstiel, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Neil Cashman, M.D.
Dr. Neil Cashman, M.D.
Chief Scientific Officer, Director
Chief Scientific Officer, Director
129.92K
+13.05%
Mr. Patrick D. Kirwin
Mr. Patrick D. Kirwin
Independent Director
Independent Director
101.12K
+2.05%
Mr. Eugene W. Williams
Mr. Eugene W. Williams
Chairman of the Board
Chairman of the Board
--
--
Ms. Anne Marie Fields
Ms. Anne Marie Fields
Managing Director
Managing Director
--
--
Ms. Maggie Shafmaster, Ph.D.
Ms. Maggie Shafmaster, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Daniel E. (Dan) Geffken, CPA
Mr. Daniel E. (Dan) Geffken, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Tue, Mar 4
Currency: USDUpdated: Tue, Mar 4
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
Canada
1.33K
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, Jul 17
Updated: Thu, Jul 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Shaf QIC LLC
15.86%
Title 19 ProMIS
10.34%
Great Point Partners, LLC
8.09%
Armistice Capital LLC
7.14%
Sphera Funds Management Ltd.
5.90%
Other
52.67%
Shareholders
Shareholders
Proportion
Shaf QIC LLC
15.86%
Title 19 ProMIS
10.34%
Great Point Partners, LLC
8.09%
Armistice Capital LLC
7.14%
Sphera Funds Management Ltd.
5.90%
Other
52.67%
Shareholder Types
Shareholders
Proportion
Hedge Fund
25.68%
Corporation
21.20%
Individual Investor
7.47%
Investment Advisor/Hedge Fund
1.78%
Investment Advisor
1.16%
Family Office
0.08%
Bank and Trust
0.06%
Research Firm
0.04%
Other
42.54%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
46
18.40M
56.28%
+443.10K
2025Q1
45
18.32M
56.87%
+570.44K
2024Q4
46
18.77M
57.42%
+658.84K
2024Q3
49
19.14M
58.55%
+4.98M
2024Q2
41
6.77M
35.75%
-201.91K
2024Q1
40
6.90M
39.50%
+44.33K
2023Q4
36
6.86M
39.39%
+553.48K
2023Q3
36
6.32M
55.88%
+2.93M
2023Q2
30
1.47M
19.09%
+793.97K
2023Q1
32
1.61M
20.90%
+800.91K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Shaf QIC LLC
2.39M
7.32%
--
--
Aug 15, 2024
Title 19 ProMIS
3.02M
9.24%
+943.68K
+45.46%
Sep 30, 2024
Great Point Partners, LLC
2.65M
8.09%
--
--
Mar 31, 2025
Armistice Capital LLC
2.33M
7.14%
-175.15K
-6.98%
Mar 31, 2025
Sphera Funds Management Ltd.
1.93M
5.9%
--
--
Mar 31, 2025
Sclar (Jeremy M.)
1.68M
5.15%
--
--
Sep 30, 2024
Ally Bridge Group NY LLC
1.48M
4.54%
-107.91K
-6.78%
Mar 31, 2025
Crocker Mountain LLC
1.16M
3.54%
--
--
Sep 30, 2024
Altium Capital Management LP
574.25K
1.76%
-7.15K
-1.23%
Mar 31, 2025
Allostery Investments LP
233.70K
0.71%
+38.59K
+19.78%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
